Canaccord lowered the firm’s price target on Passage Bio (PASG) to $67 from $260 and keeps a Buy rating on the shares. The firm decreased its peak penetration and probability of success assumptions given the evolving competitive landscape and to await more details on the safety profile.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PASG: